Invivyd Announces Selection of Potential Best-In-Class RSV Antibody Candidate VBY329; Targeting 2H 2026 IND Readiness

Stock Information for Invivyd Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Invivyd Inc.

Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
Invivyd Announces Proposed Public Offering of Common Stock
Invivyd Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025
Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.